Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment

MT Newswires Live

04/03

Akebia Therapeutics (AKBA) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.

The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.

The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.

Shares of Akebia were down more than 3% in recent Thursday trading.

Price: 1.87, Change: -0.06, Percent Change: -3.11

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2524630352"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524630352\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524630352?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-03 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524630352","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment","media":"MT Newswires Live","content":"<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.</p><p>The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.</p><p>The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.</p><p>Shares of Akebia were down more than 3% in recent Thursday trading.</p><p>Price: 1.87, Change: -0.06, Percent Change: -3.11</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-04-03 22:01</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Akebia <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (AKBA) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.</p><p>The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.</p><p>The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.</p><p>Shares of Akebia were down more than 3% in recent Thursday trading.</p><p>Price: 1.87, Change: -0.06, Percent Change: -3.11</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2524630352","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524630352","pubTimestamp":1743688914,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Akebia Therapeutics  said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.Shares of Akebia were down more than 3% in recent Thursday trading.Price: 1.87, Change: -0.06, Percent Change: -3.11","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AKBA":"Akebia Therapeutics, Inc."},"translate_title":"Akebia Therapeutics表示EMA小组建议批准Xoanacyl用于慢性肾病治疗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1},"content_text":"Akebia Therapeutics (AKBA) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.Shares of Akebia were down more than 3% in recent Thursday trading.Price: 1.87, Change: -0.06, Percent Change: -3.11","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}